Abstract Vascular endothelial growth factor C (VEGF-C) and its receptor VEGFR-3 mediate lymphangiogenesis.
Introduction
A pterygium is an elevated, superficial, external ocular mass that usually forms over the perilimbal conjunctiva, and extends onto the corneal surface. Pathologically, a pterygium is a proliferative, invasive, and highly vascularized tissue (Gebhardt et al. 2005 ). Kase et al. demonstrated that proliferation activity was high in the pterygial epithelium compared to that in the normal conjunctiva (Kase et al. 2007a, b) . Moreover, biological tissue growth and invasion are of importance in the pathology of pterygium (Bai et al. 2010) . Indeed, there are transformed cells in pterygial tissue, which is one of the characteristics of a tumor phenotype (Spandidos et al. 1997) . Recently, it has been demonstrated that significant preneoplastic lesions may be associated with the pterygium (Chui et al. 2011) , indicating that pterygia display tumor-like features.
The vascular endothelial growth factor (VEGF) family is a group of ligands for the endothelial cell-specific VEGF tyrosine kinase receptors. These growth factors play pivotal roles in the regulation of vascular and lymphatic growth. Among the VEGF family, VEGF-C and VEGF-D can stimulate the growth of lymphatic vessels, a process called lymphangiogenesis, which contributes to the pathology of various human disorders such as tumors and inflammation (Achen et al. 1998; Joukov et al. 1996) . VEGF-C is exclusively essential for the initial sprouting, and for the subsequent survival of lymphatic endothelial cells (Karkkainen et al. 2004) . VEGF-C is known to be a ligand for the endothelial cell-specific tyrosine kinase receptor, VEGFR-3. In normal adult tissues, VEGFR-3 is expressed predominantly in the lymphatic endothelial cells (Partanen et al. 2000) , while in pathological situations like chronic wound healing, VEGFR-3 can be abnormally expressed on not only lymphatic but also blood vessel endothelium (Paavonen et al. 2000; Witmer et al. 2001) .
Most studies have supported the hypothesis that VEGF-C is of prognostic value and promotes lymphatic tumor progression in various human cancers, including gastric, breast, colon, lung, head and neck, and ovarian carcinomas (Herrmann et al. 2007; Jüttner et al. 2006; Miyata et al. 2006; Trojan et al. 2006 ). In the ophthalmology field, VEGF-C and its receptor, VEGFR-3, mediate human corneal lymphangiogenesis following corneal transplantation (Cursiefen et al. 2002) . Moreover, the blockade of VEGFR-3 reportedly led to the inhibition of corneal inflammatory lymphangiogenesis (Yuen et al. 2011) , suggesting that the VEGF-C/ VEGFR-3 pathway may contribute to the discovery of a novel therapeutic target in ocular surface disorders. However, to the best of our knowledge, VEGF-C and VEGFR-3 expression has yet to be examined in the human pterygium. The aim of this study was to analyze the expression of VEGF-C and VEGFR-3 as well as lymphatic vessels in the pterygium and normal conjunctiva of humans.
Materials and methods

Preparation of human tissues
Fifteen patients with primary nasal pterygia, surgically removed, were enrolled in this study. Normal bulbar conjunctival tissues were obtained from three patients during cataract surgery. The tissues were then fixed in 4 % paraformaldehyde. After fixation, slides were washed in phosphate-buffered saline (PBS), and processed for paraffin sectioning. Written informed consent was obtained according to the Declaration of Helsinki. All human experiments conformed with the requirements of the ethics committee of Hokkaido University Graduate School of Medicine.
Conjunctival and lymphatic endothelial cell lines
Cultured human conjunctival cells were purchased from American Culture Collections (ATCC). Human Dermal Lymphatic Endothelial cell line were purchased from Promo Cell. These cell line were maintained in complete medium (Endothelial cell Growth medium 2; Promo Cell) under a humidified atmosphere containing 5 % CO 2 at 37°C.
Immunofluorescence microscopic assay
Dewaxed paraffin sections were immunostained using the complex method. Formalin-fixed, paraffin-embedded serial tissue sections were cut at a 4 lm thickness and endogenous peroxidase activity was inhibited by immersing the slides in 3 % hydrogen peroxide in methanol for 10 min. As a pretreatment, microwave-based antigen retrieval was performed in PBS. Then, non-specific binding of the primary antibody was blocked by incubating the slides in blocking bovine serum for 30 min. The slides were incubated with primary antibodies at room temperature for 2 h. The antibodies used in this study were VEGF-C (AF752) and VEGFR-3 (AF349; R&D Systems, Abingdon, UK) at concentrations of 10 and 15 lg/ml, respectively, D2-40 (1:100; Dako, Carpinteria, CA, USA), VEGF-A (1:100; abcam, Tokyo, Japan), and MUC5AC (1:200; abcam, Tokyo, Japan). Positive signals of D2-40 were visualized using diaminobendizine as a substrate. In double staining immunohistochemistry, the sections were incubated with the above-mentioned first antibody, followed by the Alexa Fluor Ò 546 goat anti-rabbit antibody for 30 min, and FITCconjugated anti-CD31 monoclonal antibody (a marker for blood endothelial cells) (1:200 Abcam, Tokyo, Japan), or FITC-conjugated anti-CD68 monoclonal antibody (a marker for macrophages) (1:200; abcam, Tokyo, Japan) for 30 min at room temperature. After washing, sections were mounted using mounting media with 4 0 ,6-diamino-2-phenylindole (DAPI; SlowFade Ò Gold antifade reagent with DAPI; Invitrogen, Eugene, OR, USA).
To investigate the correlation of VEGF-A or MUC5AC expression with VEGF-C in pterygial tissues, immunohistochemistry was performed using serial sections, with the Alexa Fluor Ò 546 goat anti-mouse secondary antibody (1:500 dilution; Invitrogen). All slides were examined using a Keyenece BZ-9000 (Keyence, Osaka, Japan) microscope.
Evaluation of VEGF-C-positive cells
In a microscopic observation, we counted the total number of epithelial cells and VEGF-C-positive cells of the pterygium and normal conjunctiva in three fields under high power (objective lens: 409). To calculate the positive rate of VEGF-C expressed in the cytoplasm of epithelial cells, the number of DAPI-positive nuclei (blue) in the epithelium was calculated in the field. And then the number of cells showing cytoplasmic immunoreactivity (red) was calculated under merged images with VEGF-C and DAPI. Cells positively stained for anti-VEGF-C antibody were noted based on the labeling index as a percentage (%) in each specimen, and the measurements were averaged.
In six out of 15 pterygium samples where pterygial head and body could be clearly separated during excision and fixation of the tissues, VEGF-C immunohistochemistry is evaluated to determine the difference of the immunolocalization. The results regarding VEGF-C in pterygial and normal conjunctival tissues are presented as the mean. In addition, VEGF-A-positive epithelial cells of the pterygium are also evaluated. The masked evaluation of histology was performed by J. F, S. K, and A. K.
Quantification of lymphatic and blood vessel densities
The lymphatic vessel density (LVD), detected by immunostaining for D2-40, was quantitatively analyzed as previously described (Aishima et al. 2008) . Briefly, areas with highly D2-40-positive vessels (hot spots) were identified by scanning the sections at low magnification (objective lens 109); then, the number of D2-40-positive vessels was counted in three fields under high power (objective lens: 409) for each case. The mean value for the three fields was calculated as the LVD for each pterygium or normal conjunctiva. Blood vessels were identified by immunostaining for CD31, in which the blood vessel density (BVD) was quantitatively analyzed as determined in the LVD. The LVD/BVD ratio was subsequently calculated in each case.
Western blot analysis
Four different subjects of pterygium and normal conjunctiva were surgically removed, and then were sonicated in lysis buffer (19 RIPA buffer; Cell Signaling Technology, Danvers, MA, USA) with protease inhibitor (Roche, Basel, Switzerland) on ice, and centrifuged at 13,500 rpm for 20 min at 4°C. These were stored at -80°C until being assayed. These samples were electrophoretically separated on SDS-PAGE using a 4 % stacking and 10 % separating gels. Proteins in gels were electro-transferred (80 V, 90 min, 4°C) to Hybond-P polyvinylidene difluoride transfer membranes (GE Healthcare, Buckinghamshire, UK). After transfer, the membranes were incubated for 1 h in a blocking solution which consisted of 5 % skim milk powder in PBS containing 1 % tween (PBST), washed briefly in PBST, and then probed with anti-VEGF-C polyclonal antibody (1:500; described above) and anti-VEGFR-3 polyclonal antibody (1:500; described above) diluted in 5 % BSA/TBST. The membrane was extensively washed in PBST for 30 min and incubated with a 1:1,000 dilution of the appropriate horseradish peroxidase-conjugated donkey anti-goat IgG at room temperature for 60 min. Then, it was placed in chemiluminescent reagent (ECL plus, GE Healthcare, Buckinghamshire, UK) and exposed to a luminescent image analyzer (Fujifilm, Tokyo, Japan). Quantification of protein expression was determined by densitometric analysis using Image J software.
VEGF-C production of cultured conjunctival cells
The cultured conjunctival epithelial cells were plated in fresh medium (2 9 10 4 cells/ml) per 60 mm petri dish in serum-supplemented medium and were incubated. In confluent condition, serum-containing medium was removed and serum-free medium was added. The culture media were then harvested 0, 24 and 48 h later, in which the concentration of VEGF-C was measured using human VEGF-C ELISA kit (R&D Systems) according to the manufacturer's instructions.
In vitro cell proliferation assay Human dermal lymphatic endothelial cells were seeded in 96-well plates at 100 ll (2 9 10 4 cells/well), and 24 h later, 10 ll of supernatant fluid containing VEGF-C described above was added to each well. The supernatant derived from cultured conjunctival epithelial cells, treated with serum-free condition decribed above, was harvested. Cell viability was assessed by a modified MTT assay using a Cell Counting Kit-8 (Dojin Laboratories, Japan) 24 and 48 h later. Results were calculated as the percentage of viability according to the manufacturer's instructions.
Statistical analysis
Student's t test was used for statistical comparison of the number of VEGF-C-positive cells, correlation with VEGF-A, LVD, and LVD/BVD ratio between pterygium and normal control groups. Differences between the means were considered significant when the probability values were \0.05.
Results
LVD is high in pterygium
D2-40-positive lymphatic vessels were clearly seen in the stroma of the pterygium and normal conjunctiva (Fig. 1,  arrows) . The LVD of the pterygium and normal conjunctiva was 8.2 ± 2.8 and 4.8 ± 0.3, respectively. The LVD was significantly higher in the pterygium than in the normal conjunctiva (p \ 0.001, Table 1 ). In contrast, the LVD/BVD ratio of the pterygium (0.86 ± 0.26) was not significant difference compared to that of the normal conjunctiva (0.71 ± 0.05) (p [ 0.05, Table 1 ).
VEGF-C is expressed in pterygium
The expression of VEGF-C in the pterygium and normal conjunctiva was evaluated by Western blot analysis and Histochem Cell Biol (2013) 139:381-389 383 immunohistochemistry. Western blot demonstrated that VEGF-C protein expression was high in total proteins extracted from the pterygial tissues, while VEGF-C expression was less marked in normal conjunctival tissues (Fig. 2a) . Table 2 summarizes the immunohistochemical results of VEGF-C in human pterygial and normal conjunctival tissues. Immunoreactivity for VEGF-C was detected in all pterygial tissues and normal conjunctiva examined. VEGF-C immunoreactivity was detected in the cytoplasm of epithelial cells in the pterygium and normal conjunctiva (Fig. 3a) . A dot graph showed all data on VEGF-C-positive rates in pterygial and normal conjunctival tissues (Fig. 3b) , indicating that this histological difference of LVD might appear gradually. In contrast, immunolocalization of VEGF-C-positive cells between pterygial head (46 %) and body (45 %) epithelia was not statistically significant difference. Immunoreactivity for VEGF-A was also detected in all pterygial tissues (Fig. 4a, b) . The number of VEGF-Aimmunopositive cells (54 %) was significantly higher than that of VEGF-C (44 %) (n = 9, p \ 0.05, Table 3 ). Immunoreactivity for VEGF-C was marginally detected in MUC5AC-positive goblet cells in pterygial epithelium (Fig. 4e-h, arrows) , and a few CD68-positive macrophages infiltrating the pterygial tissue stroma (Fig. 4i-l, arrows) .
VEGFR-3 is expressed in lymphatic vessels in pterygium
Expression of VEGFR-3 was evaluated by Western blot analysis and immunohistochemistry. As shown in Fig. 2 , Western blot showed that VEGFR-3 protein expression was strongly detected in pterygial tissues compared to normal conjunctival tissues (p \ 0.05). VEGFR-3 immunoreactivity (Fig. 5, red) was localized in the D2-40-positive lymphatic endothelial cells (Fig. 5, green) , whereas immunoreactivity for VEGFR-3 was not detected in blood vessel endothelial cells.
VEGF-C is secreted in serum-starved cultured conjunctival epithelial cells
To investigate whether conjunctival epithelial cells produce VEGF-C, we measured the levels of the VEGF-C protein concentration in the culture medium at 0, 24, and 48 h after replacement with serum-free medium. Protein concentrations of VEGF-C in the medium of 48 h (188.0 pg/mg) were significantly higher than those of 0 h (75.2 pg/mg, n = 3, p \ 0.05, Fig. 6a ).
VEGF-C promotes lymphatic endothelial cell proliferation
To investigate the role of VEGF-C in pterygium pathogenesis, we studied the effects of VEGF-C derived from conjunctival epithelial cells on cell proliferation of cultured lymphatic endothelial cells in vitro. After incubating with the supernatants 24 and 48 h after replacement of serumfree medium described above, cell viability was assessed. The former and latter supernatants were considered to have low and high VEGF-C concentrations, respectively. Addition of the supernatant obtained from low VEGF-C concentration did not have any significant effects on lymphatic cell viability examined. However, addition of supernatant obtained from high VEGF-C concentration had an increase in lymphatic cell proliferation at 24 h (n = 4, p \ 0.05, Fig. 6b ).
Discussion
In this study, we demonstrated that VEGF-C was expressed in pterygial tissues using Western blot and immunohistochemistry. Moreover, immunoreactivity for VEGF-C was clearly detected in pterygial epithelial cells. As shown in Table 2 , the present study demonstrated that the number of VEGF-C-positive cells in pterygial epithelium was significantly higher than those in normal conjunctival epithelium. It has been demonstrated that VEGF-C promotes tumor progression (Liu et al. 2011) . In fact, the pterygium displays tumor-like features (Chui et al. 2011; Spandidos et al. 1997) . VEGF-A is the most important member of VEGF family, and is known to strongly express in pterygial tissues with significant mitogenesis and cell migration. We also examined immunoreactivity for VEGF-C together with VEGF-A as a comparative study. Indeed, VEGF-Apositive rate in pterygium epithelia was significantly higher than VEGF-C. Therefore, it is indisputable that VEGF-A plays a critical role in the various pathologies. On the other hand, the results on relatively low number of VEGF-Cimmunopositive pterygial epithelial cells may reflect on more specific roles of VEGF-C in the pathology like lymphangiogenesis.
The present study demonstrated that the LVD in the pterygium was significantly higher than that in the normal conjunctiva. These results are consistent with a recently published report indicating lymphangiogenesis in human Fig. 2 Western blot analysis using anti-VEGF-C and anti-VEGFR-3 antibody. Protein expression of VEGF-C as well as VEGFR-3 is clearly detected in both pterygial and normal conjunctival tissue. Increased VEGF-C and VEGFR-3 expressions are observed in the pterygium (a). Quantification analysis reveals that VEGFR-3 expression is significantly higher in pterygium than conjunctiva (b, *p \ 0.05) , and MUC5AC (red; e, f) in serial sections, and double staining immunohistochemistry with CD68 (green: i, l), VEGF-C (j, l) and DAPI nuclear staining (blue; b, d, f, h, k, l) in pterygium. Immunoreactivity for VEGF-A is strongly detected in pterygial epithelium, where VEGF-C is partially expressed (a-d, arrow).
Immunoreactivity for VEGF-C is also detected in MUC5AC-positive goblet cells in pterygial epithelium (e-h, arrows). CD68, a marker for macrophage, reveals co-localization with VEGF-C in pterygial tissue stroma (i-l, arrows). The scale bar represents 50 lm pterygial tissues (Cimpean et al. 2011) . Moreover, we analyzed LVD/BVD ratio, which showed no significant difference in human pterygial and normal conjunctival tissues in this study. These data suggest that not only angiogenesis but also lymphangiogenesis plays a critical role in the pathology of pterygium. On the other hand, it has been demonstrated that the inhibition of VEGF-C expression reduces lymphangiogenesis (Chen et al. 2005 ).
In our investigation, the LVD, LVD/BVD ratio, and number of VEGF-C-positive epithelial cells were significantly higher in the pterygium than normal conjunctiva, suggesting that VEGF-C expression is correlated with the LVD in the pterygium. As we showed above, VEGF-C was expressed in human pterygial epithelium; however, the regulation of VEGF-C protein expression is not well understood. Recently, it was demonstrated that the expression levels of cyclooxygenase (COX)-2 were correlated with VEGF-C protein expression, and lymphangiogenesis. (Iwata et al. 2007 ) On the other hand, Chiang et al. previously stated that COX-2 was expressed in pterygial epithelium (Chiang et al. 2007) , suggesting that it may be a candidate key molecule for the regulation of VEGF-C expression. Further studies are needed to clarify the mechanism underlying VEGF-C regulation in the pterygium.
In adults, VEGFR-3 expression is limited to the lymphatic vessels (Kaipainen et al. 1995) . Under pathological conditions like chronic wound healing, VEGFR-3 is abnormally expressed on not only lymphatic but also blood vessel endothelium (Paavonen et al. 2000; Witmer et al. 2001) . In this study, we confirmed that VEGFR-3 was exclusively expressed in lymphatic vessel endothelium in human pterygial tissues. VEGF-C is a known ligand for VEGFR-3, and the overexpression of VEGF-C increases intratumoral lymphangiogenesis in breast cancer cells (Skobe et al. 2001) . Therefore, the present data suggest that VEGF-C produced by pterygial epithelial cells led to lymphangiogenesis though binding to VEGFR-3.
To investigate the role of VEGF-C in pterygium pathogenesis, we performed in vitro study of cell proliferation in lymphatic endothelial cells. Indeed, VEGFR-3 expression in the lymphatic vessels is well known. (Kaipainen et al. 1995) We revealed that cultured conjunctival epithelial cells secreted VEGF-C protein at 48 h incubation after serum-starved condition. It is well known that the cellular stress such as exposure to ultraviolet causes pterygium pathogenesis, suggesting that VEGF-C could be secreted from the conjuntival epithelium during the onset of pterygium. Addition of supernatant containing relatively high VEGF-C protein concentration derived from conjunctival epithelium had an increase in lymphatic endothelial cell proliferation. These results indicate that VEGF-C secreted from epithelial cells contributes to the lymphangiogenesis in pterygium.
VEGF-C expression is associated with the tumor phenotype, possibly making it an attractive therapeutic target. Silencing of VEGF-C suppressed tumor cell growth, migration, and invasion in vitro; tumor growth and lymphangiogenesis were suppressed by the venous injection of shRNA against VEGF-C in vivo (Feng et al. 2011) . Moreover, Padera et al. investigated the effects of the VEGFR-3 tyrosine kinase inhibitor vandetanib on the suppression of tumor growth, and the agent significantly delayed tumor growth (Padera et al. 2008) . The suppression of VEGFR-3 and its ligand VEGF-C may contribute to the regression of pterygium progression and lymphangiogenesis.
In colorectal cancer study, VEGF-C and VEGF-D were identified as biomarkers for the resistance of Avastin (Enkvetchakul et al. 2011) . Therefore, VEGF-C/VEGFR-3 pathway may be an adjunct therapeutic target for pterygia, especially, for Avastin-resistant pterygia. The limitation of this study is that this study was not available using human cultured pterygial epithelial cells and lymphatic vessels. Establishment of a definite isolation system in these cells should develop the study of lymphangiogenesis in pterygial pathology. In addition, mouse model of opthalmic pterygium has yet to be available. If it will be possible in the future, blockade of VEGF-C/VEG-FR-3 pathway by chemical agents may prove inhibition of pterygium development in vivo. Fig. 6 a Alteration of VEGF-C concentrations in the supernatants of cultured conjunctival epithelial cells. VEGF-C concentration was assessed by using VEGF-C ELISA kit 0, 24, and 48 h after replacement of serum-free medium. Concentration of VEGF-C protein in the medium of 48 h is significantly higher than that of 0 h (n = 3, *p \ 0.05). b In vitro cell proliferation assay in cultured lymphatic endothelial cells, treated with the supernatants derived from cultured conjunctival epithelial cells. After incubating with the supernatants 24 and 48 h after replacement of serum-free medium described above, cell viability was assessed. The former and latter supernatants are considered low and high VEGF-C concentrations (conc.), respectively. Cell viability of lymphatic endothelial cells treated with high VEGF-C conc. is significantly higher than that of low VEGF-C conc. at 24 h (n = 4, *p \ 0.05)
